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Objectives: Neuropsychiatric symptoms (NPSs) in dementia patients in nursing
homes are common and often treated with psychotropic drugs. Thus far, studies on
psychotropic drug use (PDU) mainly focused on elderly patients with dementia. It is
important to know the prevalence and correlates of PDU in patients with young‐
onset dementia (YOD) to optimize NPS treatment and reduce excess PDU in this
group.
Design: The Behavior and Evolution inYoung‐Onset Dementia (BEYOnD) study is a
cross‐sectional study in 230 residents with YOD in eight nursing homes providing
specialized YOD care. PDU was registered from medical charts. The influence of
age, gender, severity, and type of dementia, NPS, and agitation on PDU was analyzed.
Results: Eighty‐seven percent of the residents used psychotropic drugs, and 47%
used two or more psychotropic drugs. No significant associations with age, gender,
dementia subtype, and dementia severity were found. Depressive symptoms showed
an association with the use of antidepressants, nighttime behavior with use of hyp-
notics, and verbal agitation with antipsychotics. Apathy was strongly associated with
lower PDU.
Conclusions: Nursing home patients withYOD have a high prevalence of PDU. The
association with NPS raises questions of efficacy of these drugs in managing NPS.
Patients with apathy had a lower chance of using psychotropics. More research on
indications and effects of psychotropic drugs is needed, as well as on
(nonpharmacological) alternatives for managing challenging behavior in YOD.
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1 | INTRODUCTION
Although dementia is typically regarded as a disease of old age,
dementia also occurs at younger age. Young‐onset dementia (YOD)
with first symptom onset before the age of 651 is recognized as an
important psychosocial and medical health problem with serious con-
sequences for patients and their families.2-4
The prevalence4-6 of YOD has been estimated between 67 and 98
per 100 000 for the age of 45 to 65 years and 12 per 100 000 for the
age of 30 to 44 years. InThe Netherlands, it is estimated that there are
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approximately 12 000 people with YOD of whom approximately 2500
are residing in nursing homes.7
In patients with young onset as well as late‐onset dementia (LOD),
Alzheimer's disease is the most common cause ranging from 30% to
34% in YOD. In patients with YOD, however, there are larger propor-
tions of frontotemporal dementia (FTD), alcohol‐related dementia
(AlcD), and other causes of cognitive deterioration5,8 compared with
those with LOD.
Dementia often comes with neuropsychiatric symptoms (NPSs),
such as depression, agitation, or apathy. In YOD, research has
already demonstrated that NPSs are frequent and burdensome9
and are important predictors for institutionalization.10 However,
studies on frequency and type of NPS are scarce and show conflict-
ing results. In community‐dwelling patients with young‐onset
Alzheimer's disease (YO‐AD), these patients showed less NPS than
a comparable group with LOAD.9,11 However, in the total group of
community‐dwelling patients, those with YOD had significantly
greater levels of both hyperactive symptoms and apathy and signifi-
cantly lower levels of mood symptoms.10 In institutionalized YOD
patients, our study showed that significant NPS occurred in almost
90% of all patients, consisting most frequently of agitation (66%)
and apathy (56%), where psychotic symptoms and depressive symp-
toms were less frequent (11% and 19%, respectively). The preva-
lence and severity of NPS were higher than in institutionalized
LOD patients.12
Neuropsychiatric symptoms may be treated with psychotropic
drugs, which have limited efficacy and frequent, severe side effects.
Especially, the use of antipsychotic drugs in patients with dementia
has been shown to increase the risk of death,13,14 stroke,15,16 and car-
diac arrhythmias17 although this is not confirmed in a more recent
meta‐analysis including randomized controlled trials.18 A recent
Norwegian study in nursing home patients did not show an associa-
tion of PDU with long‐term mortality risk.19 Less controversial is the
occurrence of adverse effects such as parkinsonism,20 gait distur-
bances, and daytime sedation,21 which have been shown to negatively
influence quality of life.22
All current medical guidelines on management of NPSs in demen-
tia recommend psychosocial interventions as first‐line treatment of
NPSs. Nonpharmacological approaches have been used successfully
to reduce NPSs.23,24 Despite these recent recommendations, psy-
chotropic drugs are widely prescribed in dementia patients with
NPSs. Studies regarding psychotropic drug use in nursing home
patients with LOD found that 37% to 78% had at least one prescrip-
tion of a psychotropic drug, 21% to 54% used antipsychotics, 15%
to 31% sedatives, 9% to 38% anxiolytics, and 19% to 47%
antidepressants.25
An association between specific NPSs and the use of different
types of psychotropic drugs has been shown.26 Antipsychotic medica-
tion was more frequently prescribed in patients with at least one
NPS27,28 and more specifically in patients with psychosis, agitation,
and nighttime behavior.29
Studies on PDU in YOD patients are scarce. Thus far, after a
comprehensive search in PUBMED, only one study was found. In
this study, in community‐dwelling YOD patients, PDU30 was as high
as 52%. In a study with a comparable community‐dwelling LOD
group, this was 28.8%, and increasing age and moderate to severe
depressive symptoms were positively associated with the total use
of psychotropic drugs.31 No studies were found on PDU in institu-
tionalized YOD patients. In The Netherlands, the Dutch Knowledge
Center for YOD, a cooperation of over 20 care organizations deliver-
ing specialized care for persons with YOD, provides a unique oppor-
tunity for research in residential care for YOD. The YOD special care
units are usually part of (larger) nursing homes, delivering care for
five to 25 YOD patients per unit, with a specially trained multidisci-
plinary nursing home staff and services for younger persons. In these
nursing homes, integrated medical care is delivered by elderly care
physicians,32 who are generally responsible for all drug prescriptions
in the nursing home setting.
The aim of this study is (a) to gain insight into the point prevalence
of psychotropic drug use in institutionalized patients with YOD and (b)
to study the association between age, gender, dementia subtype,
severity of dementia, NPSs, and the use of psychotropic drugs.
2 | METHODS
2.1 | Participants
This study is part of the Behavior and Evolution in Young‐Onset
Dementia (BEYOnD) study.33 In this study, eight Dutch nursing
homes with in total 21 specialized care units for YOD patients par-
ticipated. Inclusion took place between 2005 and 2009. Patients
were considered for inclusion provided that they (a) met the
DSM‐IV‐TR criteria (American Psychiatric Association, 2000) for
dementia (b) with documented dementia symptoms in their entire
medical record before the age of 65 and (c) resided in a nursing
home with specialized care for YOD and (d) the legal representative
gave their informed consent on participation in the study. Only one
representative declined the use of her husband's data for study
purposes.
The study protocol is in accordance with the Declaration of
Helsinki, with the Dutch legislation on medical research, and it is
in agreement with the Conduct Health Research of the Dutch feder-
ation of Biomedical Scientific Societies. The study protocol was
Key points
• Psychotropic drug use is very high in patients with
young‐onset dementia in nursing homes.
• In almost half of the YOD patients, multiple psychotropic
drugs are used.
• Apathy is strongly associated with less use of
psychotropic drugs.
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approved by the Regional Medical Ethics Review Committee
Arnhem‐Nijmegen. The committee stated that, in accordance with
Dutch legislation, the study can be performed without a review pro-
cedure by the committee because in the study, only observational
data gathered by nursing staff as part of their daily work were
collected.
2.2 | Data collection
Baseline characteristics such as age, gender, marital status, and time of
institutionalization were retrieved from patients' charts.
The diagnosis and dementia subtype were retrieved from the
medical record. The type of dementia was recorded as stated in
the medical record, in the original diagnostic letter from the physi-
cian that established the diagnosis. Most patients had a comprehen-
sive medical work‐up determining the type of dementia, including
neurological and neuropsychological tests and imaging at a memory
clinic. If this was not the case, then diagnosis was recorded as not
otherwise specified.
The types of dementia were categorized into Alzheimer's dementia
(AD), vascular dementia (VaD), FTD, AlcD, and “other causes” of
dementia, including Lewy body dementia (LBD), Huntington's disease,
dementia caused by acquired brain injury, and/or encephalopathy. On
the day of inclusion, vocational nurses specifically assigned for individ-
ual patients were interviewed by the researcher (AM, elderly care phy-
sician) and a research assistant (psychologist) to collect the following
assessments.
2.3 | Assessments
The actual prescription of psychotropic drugs on the day of assess-
ment was retrieved from the medical chart, using the Anatomical
Therapeutical Chemical Classification34 and grouped into antipsy-
chotics (N05A), anxiolytics (N05B), hypnotics/sedatives (N05C), anti-
depressants (N06A), and anti‐epileptics. All psychotropic drug use
was registered, regular as well as Pro Re Nata (PRN) prescriptions. A
PRN prescription indicates the possible administration as needed but
is not necessarily administered at the assessment day.
The following data were collected for correlates. NPSs were
assessed using the Neuropsychiatric Inventory—Nursing Home (NPI‐
NH) version, Dutch version.35 The NPI‐NH includes 12 NPSs: delu-
sions, hallucinations, agitation, depression, anxiety, euphoria/elation,
apathy/indifference, disinhibition, irritability, aberrant motor behavior,
nighttime disturbances, and appetite/eating change. The frequency
and severity of each symptom are rated on a four‐point (1‐4) and
three‐point (1‐3) Likert scale, respectively.
Agitation was assessed in more detail using the Cohen‐Mansfield
Agitation Inventory (CMAI), Dutch version.36,37 The CMAI assesses
29 types of agitated behavior. The frequency of each symptom is
rated on a seven‐point scale ranging from 1 (never) to 7 (several times
an hour). The CMAI has a well‐established (test‐retest and interrater)
reliability and validity38 in nursing home patients.
Severity of the dementia was assessed using the Global Deteriora-
tion Scale,39 which consists of a seven‐point scale ranging from 1 (no
cognitive decline) to 7 (very severe cognitive decline). GDS scores of 4
to 6 denote moderate, moderately severe, and severe cognitive
decline, respectively.
2.4 | Analysis
In the analysis of NPI‐NH scores, frequency and severity scores were
multiplied, and each individual NPS was considered clinically relevant
if the frequency × severity score was more than or equal to 4, for com-
parability with previous studies on NPS in dementia.40,41 Six NPI‐NH
items were grouped into the following categories: psychosis (halluci-
nations and delusions) and agitation (agitation, disinhibition, irritability,
and aberrant motor behavior).42 For inclusion in either category, at
least one separate symptom had to be clinically relevant. Depression,
anxiety, apathy, nighttime behavior, eating changes, and euphoria
were analyzed separately.
Clinically relevant agitation as measured with the CMAI was
defined as behavior occurring at least once a week or more (frequency
score ≥ 3). CMAI items were categorized into physically nonaggres-
sive behavior, physically aggressive behavior, and verbal agitated
behavior.43
Binomial logistic regression was applied with regular psychotropic
drug use (total drug use and use of individual drug types, excluding
anti‐epileptics because the indication for the prescription could not
be verified) as the dependent variable and age (in 5‐year groups),
gender, severity of dementia, type of dementia, and NPSs as inde-
pendent variables. Two separate models were analyzed: one model
with NPI‐NH symptoms and the other model with CMAI symptoms
as independent variables for NPS. We accepted p < .05 as
significant.
3 | RESULTS
3.1 | Patients' characteristics
Two hundred thirty YOD patients met the inclusion criteria. Of five
patients, data on NPS were incomplete, resulting in inclusion of 225
patients. Patients had a mean age of 60.1 years (SD 7.3); most of
the patients had a GDS stage 6, and 53% were male (Table 1).
3.2 | Prevalence of psychotropic drug use
Over 80% of the patients used any regular prescribed psychotropic
drug (Table 2). In addition, antidementia drugs were used by 18
patients (8.0%), and anti‐epileptic drugs were used by 26% of the
patients; half of these patients had a diagnosis of epilepsy in their
medical record.
One third of the patients used one psychotropic drug; almost half
of the patients used two or more, and 17% used three or more
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psychotropic drugs (antidementia drugs and anti‐epileptics were
excluded in the combinations).
Antipsychotics, anxiolytics, and antidepressant drugs were the
most frequently prescribed drugs. The most prevalent combinations
of regularly prescribed drugs were an antipsychotic with an antide-
pressant or with an anxiolytic drug (Table 2).
3.3 | Correlates of psychotropic drug use
Results of the multivariate logistic regression analysis for correlates of
PDU are represented in Tables 3 and 4. Male gender was significantly
associated with higher PDU (OR 2.27, p = .026, and OR 2.14, p = .035,
respectively, for the two models). No significant associations between
age and PDU were found. Dementia subtype and dementia severity
were also not significantly associated with total PDU. However, anxi-
olytic drugs were less frequently prescribed in patients with GDS
stage less than or equal to 4 (or 0.12, p = .002, and/or 0.16,
p = .007, respectively, for the two models), and antipsychotics were
more frequently prescribed in non‐Alzheimer's type dementia (or
2.07, p = .045) in the NPI model.
Of the NPSs, as measured by the NPI‐NH, depression was associ-
ated with the use of antidepressants (or 2.30, p = .27); apathy was
negatively associated with psychotropic drugs in general (or 0.16,
p = .008) and with the use of hypnotics (or 0.24, p = .010). Nighttime
behavior was positively associated with the use of hypnotics (or 8.72,
p = .000).
In the analysis of the associations with agitation, as measured by
the CMAI, verbal agitation was associated with a higher risk of anti-
psychotic drug use (or 2.54, p = .002).
4 | DISCUSSION
This study is to our knowledge the first to describe the prevalence and
patient‐related correlations of psychotropic drug use of institutional-
ized YOD patients in nursing homes. Over 80% of theseYOD patients
used at least one psychotropic drug, of which antipsychotics and anti-
depressants were each used by 50% of the patients. Almost half of the
users had a combination of two or more psychotropic drugs.
Male patients had a two times higher risk of using psychotropic
drugs. Dementia severity measured by GDS showed that mild to mod-
erate dementia was associated with more use of anxiolytics than
patients in a more severe stage. Non‐AD type was associated with a
higher risk of using antipsychotics. The latter two findings should be
interpreted with caution since these effects only reached statistical
significance in the NPI model. Patients with depression had a higher
risk of using antidepressants, verbal agitation resulted in a greater risk
of using antipsychotics, and nighttime behavior was positively associ-
ated with the use of anxiolytics and sedatives.
Apathy showed a strongly negative correlation with use of psycho-
tropic drugs overall and sedatives in particular.
The prevalence rates of psychotropic drug use we found in this
study are slightly higher or in the same range compared with LOD
patients in nursing homes.25,26,44 Several studies found that lower
age was associated with higher rates of (multiple) psychotropic drug
use compared with older patients.26,27,29,45,46 We found a lower prev-
alence of PRN‐prescribed antipsychotics, although we found a higher
PRN prescription of anxiolytic drugs compared with studies with
LOD patients.29,45,47
Data on PDU in YOD patients are scarce. Some results are avail-
able from studies in community‐dwelling YOD patients. In one study,
PDU was also high30 but not as high as in the institutionalized YOD
population. In another part of the same study, it was demonstrated
that the presence of NPS was a predictor for institutionalization10
and the prevalence of NPS was substantially higher in the
TABLE 1 Patients' characteristics
Age mean, y 60.1 (range 39‐78)
<44 years 11 (5%)
45–54 43 (19%)
55–64 115 (51%)
>65 56 (25%)
Gender (% male) n (%), 120 (53%)
Dementia stage (GDS)
GDS ≤4 (mild to moderate dementia) 39 (17%)
GDS 5 (moderately severe dementia) 55 (24%)
GDS 6 (severe dementia) 68 (30%)
GDS 7 (very severe dementia) 63 (28%)
Type of dementia
Alzheimer's dementia 72 (32%)
Vascular dementia 29 (13%)
Frontotemporal dementia 36 (16%)
Alcohol‐related dementia 40 (18%)
Dementia NOS and other
types of dementia
48 (21%)
Neuropsychiatric symptoms
NPI‐NH any significant
symptoma
202 (89.8%; CI, 85.1‐93.1)
Two or more significant
symptoms
167 (74.2%; CI, 68.1‐79.5)
NPI‐NH agitation clusterb 149(66.2%; CI, 59.8‐72.1)
NPI‐NH psychosis clusterc 25 (11.1%; CI, 7.6‐15.9)
CMAI any significant symptomd 197 (87.6%; CI, 82.6‐91.2)
Abbreviations: CI, confidence interval; CMAI, Cohen‐Mansfield Agitation
Inventory; GDS, global deterioration scale; GRAD, Guidelines for the
Rating of Awareness Deficits; NOS, not otherwise specified; NPI‐NH,
Neuropsychiatric Inventory—Nursing Home.
aAny item with frequency (F) × severity (S) score more than or equal to 4.
bOne or more significant symptom(s) of agitation/aggression, disinhibition,
irritability, and/or aberrant motor behavior.
cOne or both significant symptoms of delusions and hallucinations.
dAny item occurring once a week or more.
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institutionalized group compared with the community‐dwelling group.
Since the presence and severity of NPS may be a predictor for PDU,
this may be an explanation for the higher use of PD in institutionalized
YOD patients. On the other hand, this raises the question of efficacy
of psychotropic drugs for the management of NPS. Apparently, the
NPSs are still present but may have been mitigated by the drugs to
a more acceptable level. The difference in PDU may be due not only
to differences in people with YOD or LOD but also to differences in
prescribing patterns in different countries or to the difference in
underlying diagnoses in the two groups; eg, AlcD and Huntington's
disease are known to result in relatively high PDU.48,49 Another expla-
nation may be the higher impact of agitated or aggressive behavior on
staff, thus leading to a demand for the prescription of psychotropic
drugs.50
We found an association between male gender and psychotropic
drug use in general. In literature, we find contradicting results on the
association of PDU with gender. In some LOD studies, psychotropic
drugs were positively associated with male gender44,46; other studies
found no correlation with gender28,29 or found that females are more
likely to be prescribed psychotropic drugs.26,45
Dementia severity in our study was not significantly associated
with PDU; only the use of anxiolytics showed a significant association
with dementia severity. This is in line with previous LOD stud-
ies26,29,51 finding no association with PDU in general. Assuming that
NPSs are the most important indication for PDU, the variation in
NPS, with some symptoms increasing and other symptoms subsiding
with advancing dementia,52,53 may explain the relatively stable use
of PD during the course of the disease.
In concordance with a Norwegian study,28 there were significant
associations between the different groups of drugs and specific NPSs
in the case of depressive symptoms and the use of antidepressants,
nighttime behaviors and the use of anxiolytics or hypnotics, and verbal
agitation with the use of antipsychotics.
In contrast to the aforementioned study, we found that patients
with apathy were much less likely to use psychotropic drugs in gen-
eral or sedatives in particular. This finding is in line with the current
TABLE 2 Prevalence of psychotropic drug use among patients (n = 225)
Type of Medication (ATC Code)
Regular Prescription Prescription of Medication PRN
n (% of total) n (%)
Any psychotropic drug 183 (81.3) 60 (26.)
Antipsychotic drugs (N05A) 114 (50.7) 11 (4.9)
Anxiolytic drugs (N05B) 69 (30.7) 31 (13.8)
Hypnotics (N05C) 40 (17.8) 14 (6.2)
Antidepressant drugs (N06A) 111 (49.3) 0 (0)
Single drug use
Only antipsychotic 25 (11.1)
Only anxiolytic 9 (4.0)
Only hypnotics 6 (2.7)
Only antidepressant 37 (16.4)
Total single drug use 77 (34.2)
Combination of two psychotropic drugsa
Antipsychotic + anxiolytic 17 (6.7)
Antipsychotic + hypnotics 5 (2.2)
Antipsychotic + antidepressant 28 (12.4)
Anxiolytic + hypnotics 7 (3.1)
Anxiolytics + antidepressant 8 (3.6)
Antidepressant drugs + hypnotics 2 (0.9)
Total use of two drugs 67 (29.8)
Combination of three or more drugsa
Antipsychotic + anxiolytic + antidepressant 19 (8.4)
Antipsychotic + antidepressant drugs + hypnotics 11 (4.8)
Antipsychotic + anxiolytic + hypnotics 3 (1.3)
Antipsychotic + anxiolytic + antidepressant + hypnotics 6 (2.7)
Total use of three or more drugs 39 (17.3)
aCombinations of psychotropic drugs, except antidementia drugs, and anti‐epileptic drugs.
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understanding that apathy occurs frequently in dementia as a sepa-
rate NPS requiring appropriate attention54,55 and does not have to
be the result of (excess) psychotropic drug use in nursing homes.
Apathy in YOD has an important impact on patients and their care-
givers,10 and to influence, this may be regarded as one of the most
important challenges in informal and professional care for persons
with YOD.
One of the major strengths of our study is that we had access to a
relatively large group of institutionalized YOD patients, residing in
comparable care settings with availability of complete medical records
including all prescribed drugs.
There are also some limitations to this study. First, the drug dose
was not taken into account. Therefore, it was not possible to evaluate
the dosage. Due to absence of data on the actual administration of
PRN prescriptions, PDU may be underestimated. Furthermore, rea-
sons for drug prescription, the severity of the symptoms when the
drugs were first administered, and the duration of usage were not
available for analysis, so only assumptions can be made based on
TABLE 3 Association between patient characteristics, NPS (NPI‐NH), and psychotropic drug use in Dutch nursing home patients with young‐
onset dementia
Total Psychotropic
Drugs Antipsychotic Drugs Anxiolytic Drugs Antidepressant Drugs Hypnotics
OR 95% CIb OR 95% CIb OR 95% CIb OR 95% CIb OR 95% CIb
Age 1.00 0.95 1.01 1.00 0.96 1.05 1.00 0.96 1.05 1.01 0.97 1.05 0.98 0.93 1.04
Gender (male) 2.27a 1.10 4.69 1.460 0.83 2.56 0.88 0.48 1.27 1.50 0.86 2.61 0.53 0.24 1.14
GDS 2‐5 (GDS 6‐7 reference) 0.66 0.28 1.55 1.16 0.60 2.25 0.42a 0.20 0.87 1.02 0.53 1.96 0.55 0.22 1.36
Non‐Alzheimer's type
(Alzheimer's type reference)
0.95 0.39 2.32 2.07a 1.02 4.20 1.04 0.50 2.19 0.76 0.39 1.52 0.70 0.28 1.76
NPI psychosis cluster 0.71 0.24 2.18 1.89 0.75 4.77 1.53 0.60 3.86 0.64 0.27 1.54 1.12 0.35 3.56
Agitation cluster 2.67 0.74 9.65 2.03 0.60 6.95 1.30 0.52 3.29 0.94 0.41 2.18 1.08 0.39 3.02
Depression 1.84 0.63 5.41 1.90 0.68 5.33 1.11 0.50 2.46 2.30a 1.10 4.83 0.32 0.10 1.10
Anxiety 0.75 0.25 2.28 0.86 0.27 2.75 1.24 0.53 2.92 0.71 0.31 1.64 1.18 0.39 3.62
Apathy 0.27a 0.08 0.88 0.72 0.35 1.49 0.62 0.29 1.33 0.78 0.38 1.59 0.35a 0.14 0.90
Nighttime behavior 2.13 0.46 9.87 2.47 0.97 6.31 3.08a 1.25 7.61 0.57 0.24 1.40 6.71a 2.43 18.51
Abbreviation: OR, odds ratio.
aIf value 1 is not included in the 95% confidence interval, the p value is significant (p < .05); these results are printed in bold.
b95% confidence interval (lower boundary, upper boundary).
TABLE 4 Association between patient characteristics, agitation (CMAI), and psychotropic drug use in Dutch nursing home patients with young‐
onset dementia
Total Psychotropic
Drugs
Antipsychotic
Drugs Anxiolytic Drugs
Antidepressant
Drugs Hypnotics
OR 99% CId OR 99% CId OR 99% CId OR 99% CId OR 99% CId
Age 1.00 0.95 1.05 1.00 0.96 1.05 1.00 0.95 1.04 1.01 0.97 1.05 0.97 0.92 1.03
Gender (male) 2.14e 1.05 4.34 1.61 0.91 2.83 0.96 0.53 1.73 1.42 0.82 2.44 0.69 0.34 1.40
GDS 2‐5 (GDS 6‐7 reference) 0.90 0.39 2.12 1.15 0.57 2.31 0.51 0.24 1.07 1.20 0.62 2.33 0.71 0.29 1.72
Non‐Alzheimer's type (Alzheimer's
type reference)
0.88 0.38 2.03 1.63 0.83 3.20 0.82 0.41 1.63 0.74 0.39 1.42 0.59 0.26 1.34
CMAI physically nonaggressive behaviora 1.22 .057 2.60 1.25 0.67 2.33 1.39 0.71 2.72 1.53 0.84 2.79 1.42 0.63 3.20
Physically aggressive behaviorb 1.48 0.69 3.17 1.86 0.98 3.53 1.55 0.77 3.12 0.74 0.40 1.36 1.06 0.47 2.40
Verbally agitated behaviorc 1.51 0.70 3.24 2.54e 1.39 4.65 1.28 0.67 2.44 1.44 0.80 2.59 1.11 0.52 2.36
Abbreviation: OR, odds ratio.
aPhysically nonaggressive behavior (pacing, aimless wandering, hiding things, hoarding things, trying to get to a different place, handling things inappropri-
ately, general restlessness, inappropriate dressing, or undressing).
bPhysically aggressive behavior (hitting, pushing, scratching, cursing or verbal aggression, grabbing, screaming, spitting, and strange noises).
cVerbally agitated behavior (constant unwarranted request for attention/help, complaining, repetitive sentences or questions, and negativity).43
d95% confidence interval (lower boundary, upper boundary).
eIf value 1 is not included in the 95% confidence interval, the p value is significant (p < .05).
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concomitant existence of NPS and the use of drugs. We used the type
of dementia as a determinant of psychotropic drug use, but the type
of dementia is based on the clinical diagnosis, which may not be accu-
rate in some patients.
The selection of patients in specialized YOD care units may result
in bias. In the YOD‐specialized care units, a skilled multidisciplinary
staff and a comprehensive program for NPS management are key
components of care. This may have resulted in a selection of patients
with more challenging behavior in these care units, where patients
with less NPS may be more likely to be taken care of at home or in
a regular care facility nearby. On the other hand, more skilled teams
and better equipped facilities may result in less psychotropic drug
use, compared with care for YOD patients in less adapted facilities.
Because of the amount of variables in the analysis, there is a
chance of type I error. However, for this first explorative study on
NPS in institutionalized YOD patients, we chose to keep relevant var-
iables in the model, with respect to the rule of thumb regarding the
amount of events per variable. In case of total psychotropic drug use
and the use of antipsychotics, the associations shown are strong and
reliable. However, in the case of anxiolytics and hypnotics, groups
were smaller, and therefore, the results should be interpreted with
more caution.
5 | CONCLUSION
In conclusion, we demonstrated that PDU in institutionalized YOD
patients is very high and also, the use of multiple psychotropic drugs
is widespread. A recent study showed that in only a minority of cases,
the prescriptions psychotropic drugs for NPS in dementia were
completely appropriate.56 It is likely that this is also the case in
prescriptions for YOD patients. These results show the need for
implementation of guidelines on psychotropic drug use and for
nonpharmacological options to reduce the prevalence of NPS in spe-
cialized care units.
On the basis of the results of this first study to describe the
prevalence and determinants of psychotropic drug use of patients
with YOD in nursing homes, we can conclude that more research is
needed on psychotropic drug use in patients with YOD, especially
the changes in use over time, and evaluation of effectiveness of
nonpharmacological interventions for NPS such as training of nurses,
person‐centered care, and individualized structured day programs.
Monitoring the effect of implementation of recent guidelines57 for
adequate prescription of psychotropic drug use specifically in the
YOD population may provide additional information on specific
requirements and challenges this group brings about in nursing homes.
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